February 2015, Vol 4, No 1
Enthusiasm Mounts in the Personalized Medicine Movement
It is my pleasure to welcome you to the 2015 volume of Personalized Medicine in Oncology (PMO). We are extremely enthusiastic about the forthcoming, much anticipated advances in the personalized medicine movement this year. And we’re not the only ones. Of course, those of us in the oncology community are acutely aware of the vast amount of research that has gone into establishing personalized medicine as the goal of oncology care, but now the nation at large has become aware of the promise of personalized medicine too, as exemplified even in the president’s State of the Union address last month.
More than ever, we are marching toward a future where the combination of past progress and current technologies promises to advance our ability to provide the most effective, including cost-effective, care for our patients with cancer. All of which are reflected in our pages. This year, you will note the following in PMO:
- Interview with the Innovators 2015 series: We will present eye-opening, provocative, and informative interviews with those who are shaping the landscape of personalized care in oncology
- Innovator of the Year award: Meet the current Innovator of the Year, recognized by PMO for his incredible contributions to the personalized medicine movement
- Personalized Medicine Coalition (PMC): Our collaboration with PMC continues with the
column by Dr Edward Abrahams, The Last Word
In addition, we are delighted to announce a 2015 volume of our sister publication, Immunotherapy in Oncology, to specifically cover advances in this timely and exciting realm of oncology.
Thank you for sharing our enthusiasm in the quest to personalize care by being part of our reading community. We are looking forward to a bright future in which we are able to improve the lives of our patients.
Al B. Benson III, MD, FACP, FASCO
Coeditor in Chief
Personalized Medicine in Oncology
Outcomes in adult acute lymphoblastic leukemia (ALL) remain poor, with long-term disease-free survival (DFS) rates of 30% to 40%.1 Salvage chemotherapy regimens demonstrate limited success in inducing and maintaining a second remission, and consequently overall survival (OS) at 5 years after relapse is as low as 7%.2 Therefore, novel agents [ Read More ]
The management of melanoma from the perspective of 3 regions of the world was exemplified through the presentation of a case study at the Third Annual World Cutaneous Malignancies Congress. The case, because it was managed in Latin America, was presented by Héctor Martínez-Said, MD, Melanoma Clinic and Soft Tissue [ Read More ]